Purohit Navigation, Author at STAR Therapeutics

About Purohit Navigation

This author has not yet filled in any details.
So far Purohit Navigation has created 20 blog entries.

Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
Gallery
Star Therapeutics to Present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12

Press Release

Star Therapeutics to Present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12

SOUTH SAN FRANCISCO, CA, January 5, 2026 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44^th Annual...

By Purohit Navigation|2026-01-04T09:57:56-06:00January 5, 2026|Press Release|0 Comments

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
Gallery
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

Press Release

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

SOUTH SAN FRANCISCO, CA, December 6, 2025 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose...

By Purohit Navigation|2025-12-05T16:12:14-06:00December 6, 2025|Press Release|3 Comments

Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting
Gallery
Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting

Press Release

Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting

SOUTH SAN FRANCISCO, CA, November 3, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today...

By Purohit Navigation|2025-11-02T14:31:10-06:00November 3, 2025|Press Release|0 Comments

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
Gallery
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing

Press Release

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing

SOUTH SAN FRANCISCO, CA, September 30, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing.

By Purohit Navigation|2025-10-06T17:01:47-05:00September 30, 2025|Press Release|0 Comments

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)
Gallery
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

Press Release

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

By Purohit Navigation|2025-01-06T09:01:29-06:00January 6, 2025|Press Release|1 Comment

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Gallery
Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Press Release

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, CA, January 2, 2025 – Star Therapeutics, a clinical stage biotechnology company.

By Purohit Navigation|2025-01-06T09:08:57-06:00January 2, 2025|Press Release|0 Comments

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024
Gallery
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

Press Release

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

By Purohit Navigation|2025-01-02T08:50:27-06:00December 9, 2024|Press Release|1 Comment

A PHASE IA STUDY OF VGA039, A PROTEIN S–TARGETING MONOCLONAL ANTIBODY, IN INDIVIDUALS WITH VON WILLEBRAND DISEASE DEMONSTRATES CONCENTRATION-DEPENDENT INCREASES IN THROMBIN GENERATION FOR REDUCING BLEEDING

ASH 2024 ABSTRACT #3981

By Purohit Navigation|2024-12-09T17:04:50-06:00December 9, 2024|Presentations|0 Comments

DIAGNOSIS AND DISEASE BURDEN OF VON WILLEBRAND DISEASE IN A LARGE US POPULATION–BASED DATASET

ASH 2024 ABSTRACT #3980

By Purohit Navigation|2024-12-09T17:04:37-06:00December 9, 2024|Presentations|0 Comments

DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH VON WILLEBRAND DISEASE IN A LARGE US POPULATION-BASED DATASET

ASH 2024 ABSTRACT #3978

By Purohit Navigation|2024-12-09T17:04:11-06:00December 9, 2024|Presentations|0 Comments

12 Next

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

About Purohit Navigation

THANK YOU